Form 4: Vaxcyte Director Jacks Lee Increases Stake with New Equity Awards

Vaxcyte, Inc. Director Jacks Lee was granted 3,041 restricted stock units and options to purchase 15,372 shares of common stock on June 12, 2025.

Summary

• Jacks Lee, a Director of Vaxcyte, Inc. (PCVX), acquired additional equity through new awards.
• On June 12, 2025, Lee was granted 3,041 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• Each RSU represents the contingent right to receive one share of Vaxcyte's Common Stock, with a reported acquisition price of $0.
• Additionally, Lee acquired options to purchase 15,372 shares of Common Stock.
• The stock options have an exercise price of $34.46 per share and an expiration date of June 12, 2035.
• Both the RSUs and stock options will fully vest on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, contingent on Lee's continuous service.
• Following these transactions, Jacks Lee beneficially owns 4,591 shares of Common Stock and 15,372 stock options.

Sentiment

Score: 7

Explanation: The acquisition of equity by a director is generally a positive signal, indicating confidence and aligning interests. While these are compensation awards rather than direct cash investments, they still represent a commitment to the company's future.

Positives

• Director Jacks Lee increased his beneficial ownership in Vaxcyte, Inc. through the acquisition of 3,041 Restricted Stock Units (RSUs) and options for 15,372 shares.
• The acquisition of equity by a director typically signals confidence in the company's future prospects and aligns management's interests with shareholders.

Future Outlook

This Form 4 primarily reports an insider transaction and does not contain explicit forward-looking statements or guidance about the company's future performance. However, the equity awards are structured with future vesting conditions tied to continuous service.

Industry Context

This document reports a standard insider transaction, specifically the grant of equity awards to a director, which is a common practice across all industries for executive compensation and incentive alignment. It does not provide specific insights into broader industry trends.

Related Party Transactions

• Grant of Restricted Stock Units and Stock Options to Director Jacks Lee as part of his compensation.

Stakeholder Impact

• Shareholders: Potential positive signal due to increased insider ownership and alignment of interests between management and shareholders.

Next Steps

• The Restricted Stock Units and Stock Options will vest on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Vaxcyte, PCVX, Jacks Lee, SEC Form 4, Insider Trading, Restricted Stock Units, Stock Options, Director Compensation, Equity Awards, Biotechnology, Pharmaceuticals